Cellectis (CLLS) Tax Provisions (2022 - 2026)

Cellectis (CLLS) posted quarterly Tax Provisions of -$46000.0 for Q1 2026, up 91.05% quarter-over-quarter from -$514000.0 in Q4 2025.

Analysis

Cellectis (CLLS) Tax Provisions (2022 - 2026) Analysis & Trends

Cellectis' Tax Provisions history runs 5 years deep, the most recent figure standing at -$46000.0 for Q1 2026.

In Q1 2026, Tax Provisions changed N/A year-over-year to -$46000.0; the TTM figure through Mar 2026 stood at -$560000.0 (down 113.74% YoY), while the FY2025 annual figure was -$423000.0, changed N/A from the prior year.
Tax Provisions for Q1 2026 stood at -$46000.0, up from -$514000.0 in the prior quarter.
The five-year high for Tax Provisions was $736000.0 in Q4 2023, with the low at -$514000.0 in Q4 2024.
The 5-year median for Tax Provisions is -$66500.0 (2022), against an average of -$27500.0.
The sharpest annual moves came in 2023 and 2024: Tax Provisions surged 945.98% in 2023, then plunged 169.84% in 2024.
Cellectis' Tax Provisions stood at -$87000.0 in 2022, then soared by 945.98% to $736000.0 in 2023, then slumped by 169.84% to -$514000.0 in 2024, then changed by 0.0% to -$514000.0 in 2025, then jumped by 91.05% to -$46000.0 in 2026.
Business Quant data shows CLLS's Tax Provisions at -$46000.0 in Q1 2026, -$514000.0 in Q4 2025, and -$514000.0 in Q4 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-59.00 Mn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	15.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	75.45 Mn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	13.31 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	1.90 Mn
10	Cellectis	321.90 Mn	155.05 Mn	-	-25,000.00

Historic Data

Download Data